Cargando…
A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor
INTRODUCTION: Here we present a rare case of hepatocellular carcinoma metastasis to the urinary bladder in a patient with metastatic HCC. CASE PRESENTATION: An 83‐year‐old man developed gross hematuria during combined treatment with an anti‐programmed death‐ligand 1 inhibitor and an anti‐vascular en...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622189/ https://www.ncbi.nlm.nih.gov/pubmed/37928285 http://dx.doi.org/10.1002/iju5.12625 |
_version_ | 1785130486452977664 |
---|---|
author | Miyajima, Keiichiro Urabe, Fumihiko Shunsuke, Tsuzuki Shun, Sato Takahashi, Hiroyuki Asano, Koji Yanagaki, Mitsuru Matsumoto, Michinori Ikegami, Toru Kimura, Takahiro |
author_facet | Miyajima, Keiichiro Urabe, Fumihiko Shunsuke, Tsuzuki Shun, Sato Takahashi, Hiroyuki Asano, Koji Yanagaki, Mitsuru Matsumoto, Michinori Ikegami, Toru Kimura, Takahiro |
author_sort | Miyajima, Keiichiro |
collection | PubMed |
description | INTRODUCTION: Here we present a rare case of hepatocellular carcinoma metastasis to the urinary bladder in a patient with metastatic HCC. CASE PRESENTATION: An 83‐year‐old man developed gross hematuria during combined treatment with an anti‐programmed death‐ligand 1 inhibitor and an anti‐vascular endothelial growth factor for metastatic HCC. A contrast‐enhanced CT revealed a 15 × 15 mm soft tissue mass protruding from the posterior bladder wall. Cystoscopy further revealed a solitary submucosal mass located on the posterior wall. The patient underwent transurethral resection of bladder tumor. The pathological findings were consistent with a diagnosis of bladder metastasis from HCC. Following a 3‐week interval after the surgical intervention, salvage therapy was resumed. CONCLUSION: During follow‐up after TUR‐BT in HCC patients who present with a bladder tumor, the possibility of HCC metastases to the urinary bladder should be excluded. |
format | Online Article Text |
id | pubmed-10622189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106221892023-11-03 A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor Miyajima, Keiichiro Urabe, Fumihiko Shunsuke, Tsuzuki Shun, Sato Takahashi, Hiroyuki Asano, Koji Yanagaki, Mitsuru Matsumoto, Michinori Ikegami, Toru Kimura, Takahiro IJU Case Rep Case Reports INTRODUCTION: Here we present a rare case of hepatocellular carcinoma metastasis to the urinary bladder in a patient with metastatic HCC. CASE PRESENTATION: An 83‐year‐old man developed gross hematuria during combined treatment with an anti‐programmed death‐ligand 1 inhibitor and an anti‐vascular endothelial growth factor for metastatic HCC. A contrast‐enhanced CT revealed a 15 × 15 mm soft tissue mass protruding from the posterior bladder wall. Cystoscopy further revealed a solitary submucosal mass located on the posterior wall. The patient underwent transurethral resection of bladder tumor. The pathological findings were consistent with a diagnosis of bladder metastasis from HCC. Following a 3‐week interval after the surgical intervention, salvage therapy was resumed. CONCLUSION: During follow‐up after TUR‐BT in HCC patients who present with a bladder tumor, the possibility of HCC metastases to the urinary bladder should be excluded. John Wiley and Sons Inc. 2023-08-13 /pmc/articles/PMC10622189/ /pubmed/37928285 http://dx.doi.org/10.1002/iju5.12625 Text en © 2023 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Miyajima, Keiichiro Urabe, Fumihiko Shunsuke, Tsuzuki Shun, Sato Takahashi, Hiroyuki Asano, Koji Yanagaki, Mitsuru Matsumoto, Michinori Ikegami, Toru Kimura, Takahiro A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor |
title | A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor |
title_full | A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor |
title_fullStr | A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor |
title_full_unstemmed | A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor |
title_short | A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor |
title_sort | case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622189/ https://www.ncbi.nlm.nih.gov/pubmed/37928285 http://dx.doi.org/10.1002/iju5.12625 |
work_keys_str_mv | AT miyajimakeiichiro acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT urabefumihiko acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT shunsuketsuzuki acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT shunsato acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT takahashihiroyuki acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT asanokoji acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT yanagakimitsuru acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT matsumotomichinori acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT ikegamitoru acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT kimuratakahiro acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT miyajimakeiichiro caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT urabefumihiko caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT shunsuketsuzuki caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT shunsato caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT takahashihiroyuki caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT asanokoji caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT yanagakimitsuru caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT matsumotomichinori caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT ikegamitoru caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor AT kimuratakahiro caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor |